Pacific Biosciences of California financials
$1.83+7.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.0M | $37.2M | $44.6M | $38.4M | $39.8M | $37.2M | $39.2M | $40.0M | $36.0M | $38.8M | $58.4M | $55.7M |
| Gross profit | $12.6M | $12.8M | $16.6M | $15.9M | $14.7M | -$1.4M | $10.1M | $10.0M | $5.9M | $11.3M | $9.6M | $17.9M |
| Gross margin | 32.4% | 34.5% | 37.1% | 41.4% | 36.9% | −3.7% | 25.6% | 25.0% | 16.5% | 29.1% | 16.4% | 32.1% |
| Operating income | -$44.6M | -$54.2M | -$41.2M | -$38.9M | -$44.9M | -$447.6M | -$153.0M | -$64.1M | -$175.8M | -$81.4M | -$96.5M | -$73.5M |
| Net income | -$44.7M | -$8.3M | -$40.4M | -$38.0M | -$41.9M | -$426.1M | $2.4M | -$60.7M | -$173.3M | -$78.2M | -$82.0M | -$66.9M |
| Net margin | −114.7% | −22.3% | −90.4% | −98.9% | −105.4% | −1146.8% | 6.0% | −151.9% | −481.3% | −201.4% | −140.5% | −120.1% |
| Diluted EPS | $-0.14 | $-0.03 | $-0.13 | $-0.13 | $-0.14 | $-1.44 | $0.01 | $-0.22 | $-0.64 | $-0.29 | $-0.31 | $-0.26 |
| EBITDA | -$40.8M | -$35.5M | -$37.4M | -$35.4M | -$41.2M | -$61.1M | -$52.0M | -$53.0M | -$72.3M | -$71.3M | -$86.4M | -$69.9M |
| Operating cash flow | -$35.6M | -$44.7M | -$19.1M | -$18.7M | -$29.4M | -$44.1M | -$30.6M | -$45.5M | -$54.3M | -$75.6M | -$43.6M | -$79.1M |
| Free cash flow | -$37.1M | -$47.7M | -$19.9M | -$18.8M | -$29.9M | -$45.4M | -$32.3M | -$46.3M | -$55.8M | -$79.5M | -$45.6M | -$80.0M |
| Diluted shares | 310.7M | 305.8M | 302.0M | 300.8M | 300.2M | 296.9M | 338.6M | 272.9M | 272.4M | 269.6M | 267.4M | 255.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $61.0M | $56.3M | $63.7M | $56.5M | $54.8M | $58.5M |
| Short-term investments | $175.9M | $219.7M | $215.8M | $242.2M | $259.9M | $284.6M |
| Total debt | $644.3M | $644.1M | $645.4M | $645.2M | $646.4M | $646.2M |
| Total assets | $751.9M | $782.4M | $784.1M | $803.2M | $825.5M | $860.8M |
| Total liabilities | $785.1M | $780.0M | $778.7M | $767.1M | $764.0M | $769.2M |
| Shareholders' equity | -$33.2M | $2.4M | $5.3M | $36.1M | $61.5M | $91.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology